



LIST OF ON-GOING CLINICAL TRIALS AT THE MEDICAL CITY

(As of September 2025)

Title of Clinical Trial	STATUS	ClinicalTrial.gov Identifier/PHRR NUMBER	SITE
An open-label, non-randomized, multi-center extension study to evaluate the long term safety and efficacy of APL-2 in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)	ACTIVE		THE MEDICAL CITY ORTIGAS
A randomized, double-blind, placebo-controlled phase 3 trial of Pembrolizumab (MK-3475) versus placebo in participants with Esophageal Carcinoma receiving concurrent definitive Chemoradiotherapy (KEYNOTE 975)	ACTIVE		THE MEDICAL CITY ILOILO
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn's Disease	ACTIVE		THE MEDICAL CITY CLARK
An open-label, randomized phase 3 study to evaluate efficacy and safety of Pembrolizumab (MK-3475) in combination with MK-6482 and Lenvatinib (MK-7902) or MK-1308A in combination with Lenvatinib versus Pembrolizumab and Lenvatinib as firstline treatment in participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)	ACTIVE		THE MEDICAL CITY ORTIGAS
A phase III, randomized, double-blind, placebo-controlled, multi-center study of Durvalumab Monotherapy or in Combination with Bevacizumab as Adjuvant Therapy in patients with Hepatocellular Carcinoma who are at high risk of recurrence after Curative Haptic Resection or Ablation (EMERALD-2)	Active		THE MEDICAL CITY ORTIGAS
A randomized phase 3 study evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy alone in Cisplatin-Ineligible participants with Muscle-invasive Bladder Cancer (KEYNOTE-905/EV-303)	ACTIVE		THE MEDICAL CITY ORTIGAS
A multi-center, randomized, double-blind, placebo-controlled Phase 2 clinical trial of MW33 injection to evaluate the efficacy and safety in patients with mild or moderate COVID-19	ACTIVE		THE MEDICAL CITY ILOILO
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma	ACTIVE		THE MEDICAL CITY ORTIGAS
An, adaptive, randomized, double-blind, placebo-controlled Phase II/III Trial of Monoclonal Antibody SCTA01 against SARS-CoV-2 high-risk outpatients with COVID-19 (MAOP3 TRIAL)	ACTIVE		THE MEDICAL CITY ILOILO
A phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of Adjuvant Giredestrant compared with Physician's choice of Adjuvant Endocrine Monotherapy in patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer	ACTIVE		THE MEDICAL CITY ORTIGAS

A Regional, Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Severe Uncontrolled Asthma (DIRECTION)	ACTIVE		THE MEDICAL CITY ILOILO
A phase 2, single-blinded, randomised, controlled, multi-country study to evaluate the safety, reactogenicity, efficacy and immunogenic response following sequential treatment with an anti-sense oligonucleotide (ASO) against Chronic Hepatitis-B (CHB) followed by Chronic Hepatitis-B targeted immunotherapy (CHB-TI) in CHB patients receiving nucleos(t)ide analogue (NA) therapy	ACTIVE		THE MEDICAL CITY ORTIGAS
A phase III, multi-center, randomised, double-blind, chronic dosing, parallel-group, placebo-controlled study to evaluate the efficacy and safety of two dose regimens of MEDI3506 in participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with history of COPD Exacerbations (TITANIA)	ACTIVE		THE MEDICAL CITY ILOILO
A Phase III, Randomised, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination with Tremelimumab - Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compared to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-3)	ACTIVE		THE MEDICAL CITY ORTIGAS
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care	ACTIVE		THE MEDICAL CITY CLARK
A Clinically-Oriented Antimicrobial Resistance Surveillance Network for Healthcare-associated infections (ACORN-HAI)	ACTIVE		THE MEDICAL CITY ORTIGAS
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Program to Evaluate Efficacy and Safety of filgotinib in Adult Subjects with Active Axial Spondyloarthritis	ACTIVE		THE MEDICAL CITY CLARK
The Effect Of Silybin + Phosphatidylcholine + Multivitamins + Zinc On The Non-Invasive Parameters Of Hepatic Injury In Adults With Metabolic Associated Fatty Liver Disease: A Double-Blind Randomized Placebo-Controlled Trial	ACTIVE		THE MEDICAL CITY ORTIGAS
A 2-Part Seamless Part A (Phase 2)/2Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety BIIB059 in Participants with Active Subacute Cutaneous Lupus Erythematosus with or without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)	ACTIVE		THE MEDICAL CITY CLARK
A Phase III, Multicentre, Randomised, Double-blind, 17 Chronic-dosing, Parallel-group, Placebo-controlled Extension 18 Study to Evaluate the Long-term Efficacy and Safety of 19 Tozorakimab in Participants with Chronic Obstructive 20 Pulmonary Disease (COPD) with a History of Exacerbations 21 (PROSPERO)	ACTIVE		THE MEDICAL CITY ILOILO
A Phase 3 Randomized, Double-blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome (Librexia – ACS); Version 1 (28Sep2022)	ACTIVE		THE MEDICAL CITY ORTIGAS

A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack (LibrexiaSTROKE)	ACTIVE		THE MEDICAL CITY ORTIGAS
A multicenter, placebo-controlled, randomized, double-blind, parallel-group comparison trial to investigate the efficacy and safety of brexpiprazole once-weekly (QW) formulation in patients with acute schizophrenia	ACTIVE		THE MEDICAL CITY ORTIGAS
A Multicenter, Double-blind, Randomized, Parallel-group, Phase 3 Study to Compare Efficacy and Safety of the Proposed Biosimilar PERT-IJS and EU-Perjeta along with Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Patients with Hormone Receptor Negative (HR-ve) Human Epidermal Growth Factor Receptor 2 (HER2)-positive Early Stage or Locally Advanced Breast Cancer	ACTIVE		THE MEDICAL CITY CLARK
A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma	ACTIVE		THE MEDICAL CITY ORTIGAS
Randomized, Controlled, Open-label, Phase 3, Global Multi-Center Trial to Assess the Efficacy and Safety of Ziplertinib plus Chemotherapy versus Chemotherapy alone, in Patients with Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations	ACTIVE		THE MEDICAL CITY ORTIGAS
A Randomised, Double-blind, Parallel Group, Equivalence, Multicentre Phase III Trial to Compare the Efficacy, Safety, and Immunogenicity of AP063 to Herceptin® in Subjects with HER2+ Breast Cancer	ACTIVE		THE MEDICAL CITY ORTIGAS
A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other Genomic Alterations	ACTIVE		THE MEDICAL CITY ORTIGAS
A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other Genomic Alterations	ON HOLD		THE MEDICAL CITY SOUTH LUZON
A Multicenter, Open-Label, Single-Arm, Phase 3, Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adult Participants with Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST LTE)	ACTIVE		THE MEDICAL CITY CLARK
A Phase 2a Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate to Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA (AJAX)	APPROVED		THE MEDICAL CITY PANGASINAN

A Phase 2a Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate to Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA (AJAX)	APPROVED		THE MEDICAL CITY CLARK
A Phase 3, Randomized, Double-blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome (LIBREXIA – ACS)	ACTIVE		THE MEDICAL CITY SOUTH LUZON
A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared with Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function (BalanceD-HF)	ACTIVE		THE MEDICAL CITY ORTIGAS
A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared with Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function (BalanceD-HF)	APPROVED		THE MEDICAL CITY CLARK
A Randomized, Double-blind, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS)	APPROVED		THE MEDICAL CITY PANGASINAN
A Randomized, Double-blind, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS)	APPROVED		THE MEDICAL CITY CLARK
A Randomized, Double-blind, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS)	APPROVED		THE MEDICAL CITY ILOILO
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy (PACIFIC-8) Durvalumab plus Domvanalimab	ACTIVE		THE MEDICAL CITY ORTIGAS
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of cenerimod in adult subjects with moderate to severe systemic lupus erythematosus (SLE) on top of background therapy. (IDORSIA)	APPROVED		THE MEDICAL CITY ORTIGAS
A Phase 3 Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial with Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjögren's Disease	APPROVED		THE MEDICAL CITY ORTIGAS
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of TPST-1120 in Combination with Atezolizumab plus Bevacizumab Compared with Placebo plus Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Not Previously Treated with Systemic Therapy	POSTPONED		THE MEDICAL CITY ORTIGAS
A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination with Pembrolizumab Compared with Pembrolizumab Plus Placebo as Firstline Treatment of Participants with KRAS G12C-Mutant, Metastatic NSCLC With PD-L1 TPS ≥50%	APPROVED		THE MEDICAL CITY ORTIGAS
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of abelacimab in high-risk patients	APPROVED		THE MEDICAL CITY ORTIGAS

with Atrial fibrillation who have been deemed unsuitable for oral antiCoagulation (LILAC)			
A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (sac-TMT, MK-2870) as a Monotherapy and in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple Negative Breast Cancer Expressing PD-L1 at CPS Less than 10 (TroFuse011)	Ongoing Review		THE MEDICAL CITY ILOILO
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of abelacimab in high-risk patients with Atrial fibrillation who have been deemed unsuitable for oral antiCoagulation (LILAC)	Ongoing Review		THE MEDICAL CITY ILOILO
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Felzartamab in Adults with IgA Nephropathy (PREVAIL)	Ongoing Review		THE MEDICAL CITY ORTIGAS
DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvestomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer	Ongoing Review		THE MEDICAL CITY ORTIGAS
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostal (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease	Ongoing Review		THE MEDICAL CITY ORTIGAS
Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia	Ongoing Review		THE MEDICAL CITY ORTIGAS
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer	Ongoing Review		THE MEDICAL CITY ORTIGAS
A Multicenter, Randomized, Dose-Blind, Phase 3 Long Term Extension Study to Evaluate Continuous Safety and Efficacy of Litifilimab (BILB059) in Adult Participants with Active Systemic Lupus Erythematosus	Ongoing Review		THE MEDICAL CITY ILOILO
Selatrogel Outcome Study in suspected Acute Myocardial Infarction (SOSAMI): Multi-center, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy and safety of self-administered subcutaneous selatrogel for prevention of all-cause death and treatment of acute myocardial infarction in subjects with a recent history of acute myocardial infarction	Ongoing Review		THE MEDICAL CITY ORTIGAS
Prevalence and Molecular Serotyping of Invasive Pneumococcal Disease among Adult Population in the Philippines: A Hospital-based Multi-Center, Non-Interventional Study (PrevGen-IPD)	Ongoing Review		THE MEDICAL CITY ORTIGAS



A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event

Ongoing
Review

THE MEDICAL
CITY ORTIGAS